17 results about "Acute gout" patented technology

This invention discloses a natural plant extract anti-gout product, its preparation method, and its application. The natural plant extract anti-gout product comprises the following raw material components in parts by weight: acerola cherry powder: 10-30 parts, bellflower powder: 10-30 parts, celery seed powder: 10-30 parts, peppermint leaf extract: 1-10 parts, and vitamin C: 3-15 parts. The peppermint leaf extract is concentrated at a ratio of 10:1 to 20:1 and prepared using a low-temperature extraction process. Its efficacy is clear and comprehensive: breaking through the limitations of existing single-component supplements, it constructs a three-dimensional efficacy system of "uric acid regulation - anti-inflammatory and analgesic - blood pressure auxiliary regulation." The components work synergistically to quickly relieve acute gout pain, balance blood uric acid levels in the long term, and assist in regulating blood pressure, meeting the dual needs of people with gout and hypertension. This solves the problems of limited efficacy and insufficient consideration of comorbidities in existing technologies.

The invention discloses a traditional Chinese medicine composition for treating acute gout, an external gel and a preparation method thereof, and the traditional Chinese medicine composition comprises the following raw material components in parts by mass: 5-20 parts of radix clematidis, 5-20 parts of polygonum cuspidatum, 5-20 parts of honeysuckle stem, 5-15 parts of radix aconiti preparata, 5-15 parts of pine nodular branch, 1-5 parts of corydalis tuber and 1-3 parts of asarum. The gel disclosed by the invention is an external gel prepared by researching through a traditional Chinese medicine composition intermediate extraction process and a preparation forming process, has the effective effects of directly reaching an affected part, taking effect quickly, being good in patient compliance and the like, and can realize industrial production through pilot scale-up experiment verification. Animal experiment research results show that the radix clematidis pain-relieving gel has remarkable anti-inflammatory and pain-relieving effects.

The invention discloses an internal and external compound medicine for treating gout, which comprises an oral medicament and an external medicament, the oral medicament is prepared by taking a first pharmaceutical composition as a raw material, the external medicament is prepared by taking a second pharmaceutical composition as a raw material, and the first pharmaceutical composition is prepared from herba lycopi, rhizoma alismatis, chicory and lily; the second pharmaceutical composition is prepared from the following components in parts by weight: radix aconiti preparata, rhizoma arisaematis preparata, ligusticum wallichii, caulis spatholobi and rhizoma corydalis. According to the traditional Chinese medicine composition, internal and external treatment is achieved through the oral medicament and the external medicament, the synergistic effect of the oral medicament and the external medicament can not only achieve the purpose of treating symptoms in emergency but also take'benefit 'as attack, especially for acute gout, symptoms of patients can be rapidly improved and relieved, the pain of the patients is relieved, and both symptoms and root causes are treated through different targets and multiple ways.

The present research aims to successfully establish an acute gout mouse model, and to observe the joint and organ pathological changes of the animal and detect the joint and blood related indexes to evaluate the stability of the model, so as to make an acute gout mouse model with good stability, good repeatability, practicability and closeness to clinic, facilitate further research on the pathogenesis and pathophysiological changes of acute gout, and provide a certain basis for how to implement the protective intervention measures of acute gout. The present application induces an acute gout mouse model with good stability and repeatability, practicability and closeness to clinic through injecting aromatic oil and benzopyrene into the mouse, electric shock stimulation, lithium hydroxide stimulation, hydroxyacetic acid gavage and blue light irradiation, and the acute gout model induced by multiple factors can better simulate the characteristics of human acute gout.

The invention relates to an application of an FTO inhibitor in preparation of a medicine for inhibiting acute gout. The FTO inhibitor comprises meclofenamic acid sodium (MA), entacapone or FB23-2 and pharmaceutically acceptable salts of the meclofenamic acid sodium (MA), the entacapone or the FB23-2. An acute gout model mouse is intervened by using an FTO inhibitor, in the embodiment of the invention, the swelling degree of the sole of the mouse in an MA treatment group is reduced from 1.42 + / -0.11 to 1.25 + / -0.04, the lowest point of a pain region is increased from 0.47 + / -0.11 to 0.87 + / -0.13 after 6 hours, and the protein level of IL-1beta is reduced from 18.03 + / -4.95 to 4.34 + / -1.12; the swelling degree of the soles of the mice in the FB23-2 treatment group is reduced from 1.42 + / -0.11 to 1.22 + / -0.05, the lowest point of the pain region is increased from 0.47 + / -0.11 to 0.91 + / -0.15 after 6 hours, and the protein level of IL-1beta is reduced from 9.18 + / -1.62 to 3.83 + / -0.83; the results show that the FTO inhibitor can significantly reduce the swelling degree of mouse soles, significantly increase the pain area level and significantly reduce the IL-1beta protein expression level, so that the effect of treating acute gout is achieved, and the FTO inhibitor has important significance in developing novel drugs for treating acute gout.

The invention belongs to the technical field of pharmaceutical preparations, particularly discloses a colchicine and lidocaine eutectic mixture as well as a preparation method and application thereof, and aims to solve the problems that colchicine is poor in transdermal effect, large in gastrointestinal tract side effect after oral administration and insufficient to meet the anti-inflammatory and analgesic requirements of acute gout in time. According to the invention, colchicine and lidocaine are mixed according to a molar ratio of 0.1: 0.9-0.9: 0.1 to prepare a eutectic mixture with a melting point of 46.1-64.7 DEG C through a solvent-assisted grinding method, and the eutectic mixture is also prepared into an external pharmaceutical composition. The solubility and transdermal effect of the mixture are remarkably improved, colchicine and lidocaine can be locally and efficiently delivered to lesion joints, the complementary and synergistic effects of the two drugs on anti-inflammatory and analgesic mechanisms are fully played, meanwhile, the gastrointestinal toxic and side effects of oral administration are avoided, the safety is good, the skin tolerance is good, and the application prospect is wide. The medicine is suitable for treating acute gouty arthritis.

This invention belongs to the field of biomedical technology, specifically relating to an ointment and its application. The toad oil used in this invention differs significantly in composition from toad venom, and its ointment is effective for various acute and chronic pain conditions. Animal experiments have confirmed that the toad oil ointment significantly reduces the frequency and delays the onset of acetic acid-induced writhing responses, demonstrating a clear analgesic effect. Clinical studies have shown that this ointment is rapidly effective and has a definite therapeutic effect on acute gout attacks, postherpetic neuralgia, and arthritis-related pain and swelling. The formulation effectively improves drug retention and user comfort, and no skin irritation has been observed. This development achieves comprehensive utilization of toad resources, providing an example for the sustainable development of traditional Chinese medicine and the efficient utilization of biological resources.

The application belongs to the technical field of medicine, and particularly relates to application of a beta-lactam compound in preparation of anti-inflammatory drugs. The application is found through research and verified through experiments that the beta-lactam compound is combined with the surface of alpha and beta tubulin proteins, inhibits tubulin aggregation, and thus inhibits various cell processes in which microtubules participate; the beta-lactam compound inhibits inflammatory reactions through the following pathways: inhibiting immune activation, NLRP3 inflammasome activation and Caspase-1 activation; inhibiting neutrophil recruitment, adhesion and chemokine release; inhibiting vascular endothelial growth factor secretion and endothelial cell proliferation, and thus can be used for preparing anti-inflammatory drugs, including for treating local inflammatory reaction diseases such as acute gout, familial Mediterranean fever, chronic kidney disease, pancreatitis, sarcopenia and the like caused by inflammation, and inflammation-related cardiovascular diseases such as ischemia-reperfusion injury, diabetes, atherosclerosis, pericarditis, acute coronary syndrome and the like.

The invention provides a microneedle administration method for treating gout, and relates to the field of gout administration, and the microneedle administration method comprises the following steps: S100, preparing a needle tip gel solution: mixing a gout treatment drug with hyaluronic acid, and stirring until the gout treatment drug and hyaluronic acid are completely dissolved to form a drug-loaded needle tip gel solution; s200, preparing a backing gel solution: dissolving hyaluronic acid in an aqueous solvent, and stirring until the hyaluronic acid is completely dissolved to form the backing gel solution. S300, injecting the needle tip gel solution into a needle hole of a microneedle mold, sequentially carrying out vacuum drying and centrifugal treatment to enable the needle hole to be fully filled with the solution, and drying the needle tip for 150 minutes; s400, the surface of a mold is covered with the backing gel solution, vacuum drying is conducted, and a backing layer is formed; and S500, demolding to obtain the drug-loaded microneedle patch, and attaching the drug-loaded microneedle patch to the skin of a patient to deliver a drug. The medicine is directly delivered to the corium layer through the microneedle, the liver first-pass effect and gastrointestinal tract degradation caused by oral administration are avoided, the medicine is released after microneedle puncture, and the medicine is suitable for rapid analgesia in the gout acute attack period, reduction of whole body exposure through local administration, reduction of the gastrointestinal ulcer occurrence rate of NSAIDs medicines and reduction of side effects. The length of the microneedle is 200-800 micrometers, the microneedle only penetrates through the cuticle, nerve endings are prevented from being damaged, the patch is packaged in a sterile aluminum-plastic bubble cap, a patient can attach the patch by himself / herself, and the requirement for frequently seeing a doctor is reduced.

The invention belongs to the technical field of probiotics, and relates to application of probiotics to reduction of acute gout morbidity and improvement of acute gout inflammation under continuous hyperuricemia. Furthermore, the invention relates to the application of the probiotics (Lactobacillus gasseri BKR-007) in reducing the incidence rate of acute gout and improving the inflammation of acute gout under the condition of continuous hyperuricemia. The invention finds that the strain BKR-007 can reduce the risk of gout induced by an organism under hyperuricemia by inhibiting the activity of inflammasomes NLRP3 and NF-kappa B; the inflammation level in vivo in the acute gout attack period can also be inhibited, and the swelling and pain symptom is remarkably improved; and the traditional Chinese medicine composition has a protective effect on renal function impairment caused by hyperuricemia.

The invention is applicable to the technical field of bioengineering, and provides a method for protecting an in-vitro acute gout cell model based on a polyphenol compound. According to the method, the process for ultrasonic extraction of the polyphenol compounds in the inonotus obliquus is optimized, and the optimal conditions are that the material-liquid ratio is 1: 40 g / mL, the ultrasonic time is 30 min, the ultrasonic power is 280 W, and the predicted extraction rate value is 0.866% and is verified to be 0.888%. Polyphenolic compounds (protocatechuic acid, protocatechualdehyde and osmundone) have concentration-dependent inhibition on xanthine oxidase, the ability sequence is osmundone > protocatechualdehyde > protocatechuic acid, the inhibition is reversible, and the inhibition types are competitive, miscible and miscible. Under the safe concentration, ROS, NO and LDH in acute gout model cells induced by MSU can be reduced, the activity of SOD is improved, it is prompted that inonotus obliquus has the potential hyperuricemia resisting effect, and a basis is provided for industrial production of polyphenol of inonotus obliquus.

The application provides a chlorogenic acid amide derivative, a preparation method and application thereof. The chlorogenic acid amide derivative has a structure shown in general formula I, the active carboxylic acid part in the chlorogenic acid structure is chemically modified, different alkyl / aromatic amine groups and the like are connected, and the anti-inflammatory activity of the chlorogenic acid derivative is enhanced. Meanwhile, in order to improve the fat solubility of the chlorogenic acid derivative, the phenolic hydroxyl and alcoholic hydroxyl parts and the like in the structure are protected by etherification or acylation, and the fat solubility of the chlorogenic acid derivative is improved. The chlorogenic acid amide derivative has good anti-inflammatory activity in an acute inflammatory cell model in vitro and an acute gout rat model, and is an anti-inflammatory preparation with good development potential. The synthesis method of the chlorogenic acid amide derivative is simple and efficient, and compared with original drugs, has the characteristics of increasing fat solubility and stability, improving absorption performance, improving drug efficacy and reducing toxicity and the like.

The present invention provides a traditional Chinese medicine composition for promoting spleen function and detoxification, as well as a preparation method and application thereof. The effective ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in a weight ratio: 30-45 parts of smilax glabra, 30-45 parts of gypsum, 10-15 parts of rhizoma anemarrhenae, 10-16 parts of cinnamon twig, 20-30 parts of coix seed, 10-20 parts of radix polygoni multiflori, and 10-20 parts of zedoaria. The components act synergistically to promote spleen function and eliminate dampness, clear away heat and detoxify, and have significant effects in treating acute gouty arthritis. The composition has significant advantages in improving patients' immediate pain and the traditional Chinese medicine symptoms of acute gout, and can further reduce blood uric acid and inflammatory factor levels. The preparation method is simple and suitable for large-scale industrial production.

The invention aims at providing an acute gouty arthritis diagnosis and treatment preparation based on natural antioxidants and a preparation method and application thereof, and belongs to the technical field of nano biomedical materials.The acute gouty arthritis diagnosis and treatment preparation is self-assembled with spheroidic tea polyphenol and acidified rutin as sources and comprises a polyphenol hydroxyl structure of the natural antioxidants, and the natural antioxidants are added into the polyphenol hydroxyl structure of the natural antioxidants; the nano-probe is formed by coating maleoyl bovine serum albumin (MBSA) and then coupling a NOX2 antibody through an antibody drug coupling technology, and the nano-probe with integrated diagnosis and treatment of acute gouty arthritis is constructed. The nano probe can be used for positioning an acute gouty arthritis part in real time under the guidance of near-infrared region imaging; the probe can directionally remove macrophages and microenvironment high-expression reactive oxygen species (ROS), and the preparation method of the probe is simple and easy to implement.

The invention relates to the technical field of traditional Chinese medicine compound preparations, and discloses a pharmaceutical composition and application thereof in preparation of drugs for preventing and treating hyperuricemia and gout, the pharmaceutical composition takes gentiana macrophylla as a monarch material, and focuses on expelling wind-damp, clearing damp-heat, relieving arthralgia, inhibiting uric acid generation, and promoting kidney excretion to reduce blood uric acid. Gastrodia elata and radix cyathulae serve as ministerial drugs, and gastrodia elata dispels wind, dredges collaterals The radix cyathulae has the effects of easing joint movement, guiding the medicine to move downwards and inducing And the raw lalang grass rhizome is used for reducing fever and causing diuresis, and guiding turbidity to go out. Ligusticum wallichii is used as a guide to activate blood and qi, dispel wind and relieve pain. Through targeted adjustment of the ratio of the raw materials and scientific compatibility, the effects of reducing the level of serum uric acid, remarkably improving the activity of liver uricase, synchronously improving renal function indexes, relieving hepatic and nephropathy damage, resisting acute gout and the like are achieved, and the medicine effect is remarkable.

The invention belongs to the technical field of biological medicines, and discloses application of curcumin in regulating hyperuricemia and acute gouty arthritis and a research method of curcumin. Through cell culture, establishment of a hyperuricemia and acute gout model cell model, verification of combination of curcumin and NLRP3 and NEK7 through a cell thermal migration experiment CETSA and a research system of an in-vivo animal experiment, how the curcumin regulates hyperuricemia and acute gouty arthritis through an ROS-mediated NLRP3-NEK7 inflammasome signal channel is deeply revealed. And a new perspective is provided for understanding the pathogenesis and treatment of the disease. The research method focuses on an NLRP3-NEK7 inflammasome signal channel, and provides a new therapeutic target and a new drug research and development direction for treating hyperuricemia and acute gouty arthritis. Through deep research on the pathway, a more efficient and safer therapeutic drug is expected to be developed.

The invention discloses magnetic porous carbon aerogel for blood perfusion as well as a preparation method and application thereof. The magnetic porous carbon aerogel is prepared by taking carboxylated nanocellulose and / or sodium carboxymethyl cellulose as a carbon source, bivalent copper salt and trivalent iron salt as catalytic active sites and a magnetic source, and a magnetic carrier, the magnetic porous carbon aerogel with high specific surface area, large pore capacity and hierarchical pore structure is prepared by sequentially carrying out freeze drying and inert atmosphere high-temperature calcination after carboxylation and / or carboxymethyl cellulose are / is complexed and modified by double metal ions. The raw materials used in the invention are low in cost, green and environment-friendly, the preparation method is simple, the conditions are mild, and the obtained magnetic porous carbon aerogel can be used as a biocompatible and self-antibacterial blood purification scavenger with uricase-like and antioxidant enzyme-like functions for in-vitro auxiliary treatment of intractable acute gouty kidney or gouty renal failure. And a new solution is expected to be provided for the treatment of intractable gout kidney or gouty renal failure by blood perfusion.